蛋白CD133在骨巨细胞瘤中的表达及临床意义

Expression and Clinical Significance of Protein CD133 in Giant Cell Tumor of Bone

目的 :研究蛋白CD133在骨巨细胞瘤中的表达情况,进一步探索CD133与肿瘤临床病理和预后的关系,为临床判断其生物学行为及评估预后提供有力的证据。方法 :采用免疫组织化学方法检测CD133在80例骨巨细胞瘤患者术后病理标本中的表达情况。对所有数据进行χ2检验,生存分析采用Kaplan-Meier曲线进行检验。结果 :全组骨巨细胞瘤患者1、3、5年无肿瘤复发生存率分别为93.0%、88.0%,80.0%。CD133阳性和阴性的骨巨细胞瘤患者1、3、5年无肿瘤复发生存率分别为89.0%、83.0%、75.0%和99.0%、91.0%、91.0%;其差异具有统计学意义。结论 :CD133的阳性表达与骨巨细胞瘤患者预后密切关系,是评价骨巨细胞瘤恶性程度以及评估预后的重要指标。

Objective To study the expression of protein CD133 in patients with Giant Cell Tumor of Bone(GCTB). The relationship between CD133 expression and clinical pathology prognosis and treatment efficacy and recurrence was analyzed. Methods All data were analyzed using the chi-square test, and the survival of patients was analyzed using Kaplan-Meier curves. Results The recurrent-free survival(RFS) rates of 1-year, 3-year, 5-year were 93.0%、88.0%,80.0% in all patients. In patients with positive and negative CD133, the recurrent-free survival rates of 1-year, 3-year, 5-year were 89.0%, 83.0%, 75.0% vs 99.0%, 91.0%,91.0% respectively, with statistically significant difference(P<0.05). Conclusions The positive expression of CDl33 is closely rated to the disease deterioration and recurrence of GCTB patients. CDl33 could serve as testing indicator for malignant degree of clinical evaluation and prognosis evaluation of GCTB.